Lansoprazole Treatment of Patients With Chronic Idiopathic Laryngitis: A Placebo-Controlled Trial

El–Serag, Hashem B.; Lee, Patricia; Buchner, Anna M.; Inadomi, John M.; Gavin, Michael; McCarthy, Denis M.

doi:10.1111/j.1572-0241.2001.03681.x

Cited by 188 publications

(67 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In keeping with a putative role for GERD in eliciting the symptoms, we obtained a marked reduction of the predominant ENT symptoms in the majority of patients after, on average, 4 weeks of PPI therapy with omeprazole, 20 mg b.i.d. The response rates to PPI therapy in the present study are high compared to those in a number of other publications (32,33), but we suspect that this mainly reflects patient selection and is in line with our own previous observations (22)(23)(24)(25). We recruited consecutive patients from the ENT clinic for a full reflux investigation, while we suspect that previous studies dealt with selected ENT patients referred to the gastroenterologist because of particularly difficult and refractory symptoms.…”

Section: Discussionsupporting

confidence: 83%

Determinants of Long-Term Outcome of Patients with Reflux-Related Ear, Nose, and Throat Symptoms

2006

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is present in up to 75% of patients with chronic refractory ear, nose, and throat (ENT) symptoms, and proton pump inhibitor (PPI) therapy induces symptom relief in the majority of these patients. It has been suggested that endoscopic findings and quantification of esophageal acid exposure may help to predict the long-term outcome of medical therapy, but prospective studies that confirm this hypothesis are lacking. The aim of the present study was to investigate the relationship of endoscopic findings and quantification of reflux with long-term outcome in patients with reflux-related ENT symptoms. One hundred six consecutive patients with chronic refractory unexplained ENT symptoms underwent upper GI endoscopy, 24-hr dual-channel esophageal pH and Bilitec (n = 35) monitoring, and esophageal manometry. Subsequently, all were treated with omeprazole, 20 mg b.i.d., and patients were followed at 2-week intervals until symptom relief. Four weeks later, omeprazole therapy was gradually decreased and the lowest effective omeprazole maintenance dose, if any, was determined. Eighty-one patients (49 men; mean age, 50) experienced a clear or excellent therapeutic response after, on average, 4 weeks of omeprazole, 20 mg b.i.d. In 36 patients (44%; group A), PPI treatment could be stopped completely, 27 patients (33%; group B) required a maintenance dose of omeprazole, 20 mg/day, and 18 patients (22%; group C) required maintenance with omeprazole, 40 mg/day. The prevalence of reflux esophagitis was significantly lower in group A patients, who also had significantly lower distal esophageal acid exposure, proximal esophageal acid exposure, and esophageal duodenogastroesophageal reflux exposure compared to groups B and C. Multivariate analysis identified the presence of esophagitis and pathological distal esophageal acid exposure as risk factors for the need of maintenance therapy. In patients with reflux-related ENT symptoms, initial findings on upper GI endoscopy and 24-hr pH-metry help to predict the need for maintenance therapy.

show abstract

Section: Discussionsupporting

confidence: 83%

Determinants of Long-Term Outcome of Patients with Reflux-Related Ear, Nose, and Throat Symptoms

2006

View full text Add to dashboard Cite

show abstract

“…To use higher than approved doses of PPI is suggested in some situations [16]. One of the times that this is of particular benefit is during a diagnostic trial for supraesophageal symptoms of GERD [17]. Several studies have suggested that the empiric therapy has to be aggressive, with a period of treatment of at least 2-3 months [1,18,19].…”

Section: Treatmentmentioning

confidence: 99%

Effect of Antisecretory Therapy on Atypical Symptoms in Gastroesophageal Reflux Disease

et al. 2007

View full text Add to dashboard Cite

The effect of proton pump inhibitor (PPI) therapy on extraesophageal or atypical manifestations of gastroesophageal reflux disease (GERD) remains unclear. This study aimed to evaluate the prevalence of atypical manifestations in patients with acid reflux disease and the effect of PPI treatment. Patients with symptoms and signs suggestive of reflux were enrolled. Erosive esophagitis was stratified using the Los Angeles classification. Demographic data and symptoms were assessed using a questionnaire and included typical symptoms (heartburn, regurgitation, dysphagia, odynophagia), and atypical symptoms (e.g., chest pain, sialorrhea, hoarseness, globus sensation, chronic coughing, episodic bronchospasm, hiccup, eructations, laryngitis, and pharyngitis). Symptoms were reassessed after a 3-month course of b.i.d. PPI therapy. A total of 266 patients with a first diagnosis of GERD (erosive, 166; non-erosive, 100) were entered in the study. Presentation with atypical symptoms was approximately equal in those with erosive GERD and with non-erosive GERD, 72% vs 79% (P = 0.18). None of the study variables showed a significant association with the body mass index. PPI therapy resulted in complete symptom resolution in 69% (162/237) of the participants, 12% (28) had improved symptoms, and 20% (47) had minimal or no improvement. We conclude that atypical symptoms are frequent in patients with GERD. A trial of PPI therapy should be considered prior to referring these patients to specialists.

show abstract

“…All studies have failed to show a significant effect of PPIs over placebo [3,4], except one [5] that included a very low number of patients and had a 0% placebo response. Up to 50% of the patients with GERD may require continuous medical therapy to prevent relapse [6].…”

mentioning

confidence: 96%

The effect of laparoscopic Nissen fundoplication on laryngeal findings and voice quality

et al. 2007

View full text Add to dashboard Cite

show abstract

Lansoprazole Treatment of Patients With Chronic Idiopathic Laryngitis: A Placebo-Controlled Trial

Abstract: Empirical treatment with lansoprazole is efficacious in relieving symptoms of laryngitis compared to placebo. Such treatment can be considered as a first-line option in managing patients with idiopathic chronic laryngitis.

Cited by 188 publications

References 18 publications

Determinants of Long-Term Outcome of Patients with Reflux-Related Ear, Nose, and Throat Symptoms

Determinants of Long-Term Outcome of Patients with Reflux-Related Ear, Nose, and Throat Symptoms

Effect of Antisecretory Therapy on Atypical Symptoms in Gastroesophageal Reflux Disease

The effect of laparoscopic Nissen fundoplication on laryngeal findings and voice quality

Contact Info

Product

Resources

About